RxDoctor Payments Data

Janice Miyakawa, MD

Family Medicine · Santa Monica, CANPI 1487684064

Payments from drug & device makers

$1,542in general payments, 2019–2025

Across 42 payments — averaging $36.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$608
  • Novo Nordisk$400
  • Lilly USA, LLC$124
  • Merck$115
  • Recordati_rare_diseases_inc.$104
  • Bayer$58
  • plus $133 from 6 others

What the payments were for

  • Food & beverage$1,542100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen10$608
Novo Nordisk18$400
Lilly USA, LLC4$124
Merck1$115
Recordati_rare_diseases_inc.1$104
Bayer2$58
AstraZeneca1$33
Alnylam Pharmaceuticals Inc.1$27
GSK1$21
Metuchen Pharmaceuticals1$21
Janssen Scientific Affairs, LLC1$18
Pfizer1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,542 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$80,308
Medicare patients
248
Services billed
1,633

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProliaDenosumab12$19,721
EstringEstradiol17$8,770
Estradiol84$7,950
SynthroidLevothyroxine Sodium52$3,480
Testosterone15$2,895
Atorvastatin Calcium312$2,823
Duloxetine Hcl43$2,172
Levothyroxine Sodium139$1,626
Rosuvastatin Calcium113$1,487
Losartan Potassium107$1,460
YuvafemEstradiol13$1,457
PaxlovidNirmatrelvir/Ritonavir22$1,429
Potassium Citrate ErPotassium Citrate11$1,155
Estradiol (Twice Weekly)Estradiol12$1,116
Valsartan28$1,021

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenProlia$608$19,72112 claims
PfizerEstring, Paxlovid$13$10,19939 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in Santa Monica

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →